Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. We work alongside a broad range of customers – from emerging biotechs to global pharmaceutical companies – to transform their therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Our vision is to be the pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology and lean manufacturing.
Founded in 1897 in the Swiss Alps, our business has embraced innovation and kept pace with a fast-changing world for more than 125 years. As the first and the original CDMO, we have been manufacturing medicines for more than four decades. Today we offer one of the largest Western CDMO networks with a global team of 18,500 colleagues working across more than 30 sites in five continents. Our people are united by a common purpose: to turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Discover more about our One Lonza strategy here.
Our business is structured to meet our customers’ complex needs across three synergistic Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities. Our services span from early development to drug substance and drug product manufacturing, and we lead in both established and emerging technologies including mammalian biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, microbial, and cell and gene. Across technologies, we deliver integrated solutions to meet our customers’ needs throughout the entire treatment lifecycle.
Our company generated sales of CHF 6.6 billion with a CORE EBITDA of CHF 1.9 billion in Full-Year 2024. Lonza shares are listed on the SIX Swiss Exchange and Swiss Market Index (SMI), with a secondary listing on the SGX Singapore Exchange.